Compare QNC & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | QNC | MYGN |
|---|---|---|
| Founded | 2007 | 1991 |
| Country | Canada | United States |
| Employees | 5 | N/A |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 434.7M | 444.2M |
| IPO Year | 2026 | 1996 |
| Metric | QNC | MYGN |
|---|---|---|
| Price | $2.22 | $3.28 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $7.64 |
| AVG Volume (30 Days) | 621.4K | ★ 2.3M |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $771,400,000.00 |
| Revenue This Year | N/A | $6.86 |
| Revenue Next Year | N/A | $5.45 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2.33 |
| 52 Week Low | $1.90 | $2.74 |
| 52 Week High | $3.59 | $8.59 |
| Indicator | QNC | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 44.07 | 29.53 |
| Support Level | $1.91 | $2.74 |
| Resistance Level | $2.31 | $5.17 |
| Average True Range (ATR) | 0.13 | 0.29 |
| MACD | 0.04 | -0.25 |
| Stochastic Oscillator | 78.05 | 16.98 |
Quantum eMotion Inc is dedicated to developing of a new generation of quantum-safe encryption for the quantum computing age. It is a developer of a new generation of cryptographic solutions under the acquisition of licenses. It allows clients and partners to develop secure quantum-safe encryption that can protect anything from consumer and enterprise devices like mobile phones, computers, the Internet of Things, and networking equipment to demanding cloud-based applications, servers, and military devices.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.